N/A N=226 The Resource Information Program for Parents on Lifestyle and Education
Pediatric Obesity
Primary: Feasibility (Parents' Interest in the SBIRT.) — 84.3; NA; NA; NA percentage of parents
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=200 Safety and Efficacy of Xenical in Children and Adolescents With Obesity-Related Diseases
Diabetes Mellitus · Hypertension · Metabolic Disease
Primary: Change in BMI Standard Deviation Score — -0.12; -0.06 Standard Deviation Score — p=0.007
N/A N=472 Family Obesity Intervention: Motivational Interviewing and Community Support
Obesity
Primary: Change in Adult Body Mass Index — 0.3; -0.1 kg/m2 — p=0.67
N/A N=697 Enhancing Self Regulation as a Strategy for Obesity Prevention in Head Start Preschoolers
Obesity
Primary: Change in Body Mass Index Z-score — -0.01; 0.00; -0.04 Z-Score
Phase 2 N=60 Metformin in Kidney Disease
Chronic Kidney Disease · Cardiovascular Disease · Metabolic Syndrome
Primary: Change is Leptin to Adiponectin Ratio (LAR) — 2.2; 1.3; 1.3; 1.4 ng/micrograms
N/A N=40 Childhood Risk Reduction Program in Hispanics
Breast Feeding, Exclusive
Primary: Exclusive Breastfeeding (EBF) — 9; 4; 11; 13 Participants
N/A N=76 Study of Brain, Reward, and Kids' Eating
Obesity, Childhood · Eating Behavior
Primary: Child Body Mass Index — 17.83; 18.78 kg/m-squred
N/A N=30 Estrogen Sensitivity and Ovulatory Dysfunction in Obesity
Obesity · Infertility
Primary: Luteinizing Hormone Pulse Amplitude — 2.73; 1.12 IU/L
N/A N=26 The Effect of Montelukast on Asthma Control in Overweight/Obese Atopic Asthmatics
Asthma · Obesity · Inflammation
Primary: Asthma Control Test (ACT) Scores — 25.00; 20.5; 24.00; 15.75 units on a scale
Phase 1 N=71 Pharmacokinetics of Pantoprazole and CYP2C19 Activity in Children and Adolescents With GERD: A Pilot Study
Obesity · GERD
Primary: Pantoprazole Apparent Oral Clearance — 0.42; 0.29; 0.23 L/hr/kg
N/A N=511 DVD Lifestyle Intervention
Obesity
Primary: Body Weight — 99.8; 101.0 kilogram (kg) — p=0.001
N/A N=197 Laparoscopic Gastric Bypass vs LAP-BAND for Treatment of Morbid Obesity
Morbid Obesity
Primary: Excess Weight Loss From Pre-operation to 5 Years Post-operation — 68.4; 45.4 percent change
N/A N=21 Investigation of a New Diet for the Treatment of Obesity in the NHS
Obesity
Primary: Body Weight Change — -12.99 kg — p=<0.0001
N/A N=77 Study of Growth Hormone and Bone in Obesity
Obesity · Osteopenia
Primary: Bone Mineral Density — -0.015; -0.008 grams/cm^2
Phase 2 N=66 Enhancing Weight Loss Maintenance With GLP-1RA (BYDUREON™) in Adolescents With Severe Obesity
Severe Obesity
Primary: Body Mass Index — 10.1; 4.6 percentage (body mass index)